Finnish efficacy trials with Haemophilus influenzae type b vaccines.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 1588148.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The first Finnish trial with Haemophilus influenzae type b vaccine was conducted during 1973-1974. It demonstrated that the polysaccharide vaccine was 90% efficacious in children greater than or equal to 18-24 months old. The immunologically superior polysaccharide-protein conjugate vaccines have been used since 1986 in randomized trials. The PRP-D vaccine (polysaccharide conjugated to diphtheria toxoid) was 90% efficacious when given at 3, 4, and 6 months of age to 58,000 infants. In 1988-1989, the PRP-D vaccine was compared with the HbOC vaccine (oligosaccharide conjugated to CRM197 protein). Follow-up is continuing, but both vaccines seem to be efficacious after two doses in infancy.
Medical subject headings
- Bacterial Proteins
- Bacterial Vaccines
- Diphtheria Toxoid
- Haemophilus Infections
- Haemophilus Vaccines
- Haemophilus influenzae
- Tetanus Toxoid